keyword
MENU ▼
Read by QxMD icon Read
search

Immunomodulator

keyword
https://www.readbyqxmd.com/read/28329582/cyclosporine-in-toxic-epidermal-necrolysis-a-brief-review-of-the-emerging-therapeutic-modality
#1
Piyush Kumar, Nilay Kanti Das
Toxic epidermal necrolysis (TEN) is a severe life-threatening adverse drug reaction that predominantly involve the skin and mucous membranes, and is associated with high mortality (25-35% or even higher) and with various long term sequelae. There is no universally accepted treatment for TEN, but key elements of management include rapid diagnosis, identification and interruption of the culprit drug, evaluation of the prognosis using SCORTEN, specialized supportive care ideally in an intensive care unit, and consideration of immunomodulating agents...
October 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28329382/systemic-immunomodulating-therapies-for-stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-a-systematic-review-and-meta-analysis
#2
Stefanie Zimmermann, Peggy Sekula, Moritz Venhoff, Edith Motschall, Jochen Knaus, Martin Schumacher, Maja Mockenhaupt
Importance: Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but severe adverse reactions with high mortality. There is no evidence-based treatment, but various systemic immunomodulating therapies are used. Objectives: To provide an overview on possible immunomodulating treatments for SJS/TEN and estimate their effects on mortality compared with supportive care. Data Sources: A literature search was performed in December 2012 for articles published in MEDLINE, MEDLINE Daily, MEDLINE Inprocess, Web of Science, EMBASE, Scopus, and the Cochrane Library (Central) from January 1990 through December 2012, and updated in December 2015, in the English, French, Spanish, and German languages looking for treatment proposals for SJS/TEN...
March 22, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28328624/long-term-maintenance-of-clinical-endoscopic-and-radiographic-response-to-ustekinumab-in-moderate-to-severe-crohn-s-disease-real-world-experience-from-a-multicenter-cohort-study
#3
Christopher Ma, Richard N Fedorak, Gilaad G Kaplan, Levinus A Dieleman, Shane M Devlin, Nathan Stern, Karen I Kroeker, Cynthia H Seow, Yvette Leung, Kerri L Novak, Brendan P Halloran, Vivian W Huang, Karen Wong, Philip K Blustein, Subrata Ghosh, Remo Panaccione
BACKGROUND: Ustekinumab is a monoclonal antibody targeting interleukins 12 and 23. While effective in clinical trials for Crohn's disease (CD), long-term maintenance of response in the real-world setting is unclear. We aim to assess the efficacy of ustekinumab for maintaining clinical, endoscopic, and radiographic response in CD. METHODS: A retrospective multicenter cohort study was performed on patients with CD achieving steroid-free clinical response to ustekinumab induction, and advanced onto a regularly scheduled maintenance ustekinumab regimen between 2011 and 2016...
March 21, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28326334/bactericide-immunomodulating-and-wound-healing-properties-of-transgenic-kalanchoe-pinnata-synergize-with-antimicrobial-peptide-cecropin-p1-in-vivo
#4
A A Lebedeva, N S Zakharchenko, E V Trubnikova, O A Medvedeva, T V Kuznetsova, G A Masgutova, M V Zylkova, Y I Buryanov, A S Belous
Procedure of manufacturing K. pinnata water extracts containing cecropin P1 (CecP1) from the formerly described transgenic plants is established. It included incubation of leaves at +4°C for 7 days, mechanical homogenization of leaves using water as extraction solvent, and heating at +70°C for inactivating plant enzymes. Yield of CecP1 (after heating and sterilizing filtration) was 0.3% of total protein in the extract. The water extract of K. pinnata + CecP1 exhibits favorable effect on healing of wounds infected with S...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28325871/progression-of-type-1-diabetes-from-the-prediabetic-stage-is-controlled-by-interferon-%C3%AE-signaling
#5
Brett S Marro, Brian C Ware, Jaroslav Zak, Juan Carlos de la Torre, Hugh Rosen, Michael B A Oldstone
Blockade of IFN-α but not IFN-β signaling using either an antibody or a selective S1PR1 agonist, CYM-5442, prevented type 1 diabetes (T1D) in the mouse Rip-LCMV T1D model. First, treatment with antibody or CYM-5442 limited the migration of autoimmune "antiself" T cells to the external boundaries around the islets and prevented their entry into the islets so they could not be positioned to engage, kill, and thus remove insulin-producing β cells. Second, CYM-5442 induced an exhaustion signature in antiself T cells by up-regulating the negative immune regulator receptor genes Pdcd1, Lag3, Ctla4, Tigit, and Btla, thereby limiting their killing ability...
March 21, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28325631/new-concepts-of-personalized-therapy-in-salivary-gland-carcinomas
#6
REVIEW
Gunter Keller, Diana Steinmann, Alexander Quaas, Viktor Grünwald, Stefan Janssen, Kais Hussein
Salivary gland carcinomas are rare tumours and therapy strategies are less standardized than in lung, gastric or breast cancer. Therapy is based on surgery, but not all carcinomas are completely resectable, e.g. because carcinomas often show infiltration of nerves. For further therapy decision pathology is recommended, but evaluation of potential targets for personalized therapy is not part of the routine panel. Many salivary gland carcinomas can be resistant to radio- and/or chemotherapy, which limits therapeutic options...
March 18, 2017: Oral Oncology
https://www.readbyqxmd.com/read/28324879/quantitative-analysis-of-uveitis-macular-edema-in-multiple-sclerosis-patients-receiving-deep-posterior-sub-tenon-triamcinolone-acetonide-injection
#7
Svetlana Jovanović, Tatjana Šarenac Vulović, Filip Radotić, Zorica Tončić, Maja Živković, Nenad Petrović
AIM: We aimed to analyze the effects of adjunctive posterior sub-Tenon capsule triamcinolone acetonide injection in the treatment of intermediate uveitis macular edema in multiple sclerosis patients that could not be controlled by systemic corticosteroid medications and immunomodulators. METHODS: The study included 30 eyes of 25 patients with multiple sclerosis who received a posterior sub-Tenon injection of 40 mg/mL triamcinolone acetonide. Parameters monitored for therapy efficiency were best-corrected visual acuity, intraocular pressure, central foveal thickness (CFT), and fluorescein angiography (FA) scores...
March 22, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28324804/high-density-lipoprotein-immunomodulates-the-functional-activities-of-macrophage-and-cytokines-produced-during-ex-vivo-macrophage-cd4-t-cell-crosstalk-at-the-recent-onset-human-type-1-diabetes
#8
Ibtissem Benghalem, Warda Meziane, Zeyneb Hadjidj, Lamia Ysmail-Dahlouk, Ahmed Belamri, Kheira Mouhadjer, Mourad Aribi
BACKGROUND: Both CD4(+) T cells and macrophages are mainly involved in the autoimmune-mediated β-cells destruction in type 1 diabetes (T1D). The aim of this study was to examine the effect of HDL on functional activities of macrophage and its ability to regulate the production of cytokines in autologous mixed macrophage/CD4(+) T cells at the recent-onset human type 1 diabetes. METHODS: Cell samples were isolated from volunteers with recent-onset T1D or healthy controls...
March 16, 2017: Cytokine
https://www.readbyqxmd.com/read/28319748/modulation-of-vascular-function-and-anti-aggregation-effect-induced-by-1%C3%A2-3-1%C3%A2-6-%C3%AE-d-glucan-of-saccharomyces-cerevisiae-and-its-carboxymethylated-derivative-in-rats
#9
Lorena Soares Bezerra, Marciane Magnani, Raul Jorge Hernan Castro-Gomez, Hassler Clementino Cavalcante, Tays Amanda Felisberto da Silva, Renata Layne Paixão Vieira, Isac Almeida de Medeiros, Robson Cavalcante Veras
BACKGROUND: β-d-Glucans are polysaccharides found in the cell walls of yeasts, such as Saccharomyces cerevisiae, and they have been studied because of their beneficial effects on health, mainly in terms of immunomodulation. However, information on the action of these polymers on vascular and platelet function is still scarce. This study evaluate the effect of (1→3) (1→6) β-d-glucan (βG-Sc) and its carboxymethylated derivative (CM-G) on vascular and platelet function in rats. METHODS: The animals received daily oral treatments with βG-Sc (20mg/kg) and CM-G (20mg/kg) for eight days...
January 12, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/28319073/ex-vivo-t-cell-depletion-in-allogeneic-hematopoietic-stem-cell-transplant-past-present-and-future
#10
REVIEW
A Saad, L S Lamb
The most common cause of post-transplant mortality in patients with hematological malignancy is relapse, followed by GvHD, infections, organ toxicity and second malignancy. Immune-mediated complications such as GvHD continue to be challenging, yet amenable to control through manipulation of the T-cell compartment of the donor graft with subsequent immunomodulation after transplant. However, risk of both relapse and infection increase concomitantly with T-cell depletion (TCD) strategies that impair immune recovery...
March 20, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28317057/synthesis-and-evaluation-of-a-tag-free-photoactive-phospho-ceramide-analogue-1-pcera-1-probe-to-study-immunomodulation-in-macrophages
#11
Rambabu Dandela, Roi Mashiach, Raju Adepu, Rachel Gregor, Muhammad Athamna, Efrat Zecharia, Orna Ernst, Tsaffrir Zor, Michael M Meijler
Phospho-ceramide analogue-1 (PCERA-1), a synthetic analogue of ceramide-1-phosphate (C1P), has been previously shown to act as a potent modulator of macrophage activity and inflammation. We have developed an efficient synthesis of PCERA-1 from readily available starting materials, and designed and prepared derivatives of this analogue, including a photoaffinity probe to tag and identify putative proteins that bind PCERA-1.
March 20, 2017: Chemical Communications: Chem Comm
https://www.readbyqxmd.com/read/28316391/antileishmanial-and-immunomodulatory-potential-of-ocimumsanctum-linn-and-cocosnucifera-linn-in-murine-visceral-leishmaniasis
#12
Gaurav Bhalla, Sukhbir Kaur, Jaspreet Kaur, Rupinder Kaur, Puneet Raina
The role of immunomodulation in the therapeutic treatment of visceral leishmaniasis has gained eminence in view of moderate to severe drawbacks of the currently available drugs like toxicity, drug resistance and prohibitive costs. The potential for modulation of the immune system of many herbal plants can be tapped to address these problems. We conducted the present research study to investigate the antileishmanial and immunomodulatory effects of Ocimum sanctum Linn. and Cocos nucifera Linn. during the progression of visceral leishmaniasis in BALB/c mouse model...
March 2017: Journal of Parasitic Diseases: Official Organ of the Indian Society for Parasitology
https://www.readbyqxmd.com/read/28316250/adalimumab-in-ulcerative-colitis-efficacy-safety-and-optimization-in-the-era-of-treat-to-target
#13
Miles P Sparrow
Active ulcerative colitis is associated with significant morbidity and impairment to quality of life. Adalimumab is a welcome addition to the therapeutic armamentarium for clinicians treating patients with moderate-severe ulcerative colitis refractory to conventional therapies, an indication with few prior treatment options. It offers the convenience of self-injection and is most appropriate for outpatients with moderate disease activity. Areas covered: This review briefly summarizes data from well-designed clinical trials and observational real-life studies that demonstrate the safety and efficacy of adalimumab in UC...
March 20, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28315822/protective-effect-of-zerumbone-reduces-lipopolysaccharide-induced-acute-lung-injury-via-antioxidative-enzymes-and-nrf2-ho-1-pathway
#14
Wai-Shing Leung, Ming-Ling Yang, Shiuan-Shinn Lee, Chi-Wen Kuo, Yung-Chyuan Ho, Rosa Huang-Liu, Hui-Wen Lin, Yu-Hsiang Kuan
Acute lung injury (ALI) is a serious disease with high morbidity and mortality rate. Although there are effective strategies for treatment of ALI; a widely accepted specific pharmacotherapy has not yet established. Zerumbone, the major active phytochemical compound from Zingiber zerumbet Smith, exhibits various beneficial biological and pharmacological activities, such as antioxidation, anti-inflammation, immunomodulation, and anti-cancer. We aimed to study the potential protective effects and mechanisms of zerumbone in mouse model of lipopolysaccharide (LPS)-induced ALI...
March 15, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/28314084/treatment-patterns-and-outcome-following-initial-relapse-or-refractory-disease-in-patients-with-systemic-light-chain-amyloidosis
#15
Nidhi Tandon, Surbhi Sidana, Morie A Gertz, Angela Dispenzieri, Martha Q Lacy, Francis K Buadi, David Dingli, Amie L Fonder, Miriam A Hobbs, Suzanne R Hayman, Wilson I Gonsalves, Yi Lisa Hwa, Prashant Kapoor, Robert A Kyle, Nelson Leung, Ronald S Go, John A Lust, Stephen J Russell, Steven R Zeldenrust, S Vincent Rajkumar, Shaji K Kumar
We analyzed the outcomes following initial relapse or refractory disease in systemic light chain amyloidosis (AL) and the impact of type of therapy employed.A total of 1327 patients with AL seen at Mayo Clinic within 90 days of diagnosis, between 2006 and 2015, were reviewed. The study included 366 patients experiencing a documented hematological or organ relapse or refractory disease requiring start of second line therapy. Overall survival (OS) and time to next treatment (TTNT) were calculated from start of second line treatment...
March 17, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28304217/the-efficacy-of-teriflunomide-in-patients-who-received-prior-disease-modifying-treatments-subgroup-analyses-of-the-teriflunomide-phase-3-temso-and-tower-studies
#16
Mark S Freedman, Jerry S Wolinsky, Giancarlo Comi, Ludwig Kappos, Tomas P Olsson, Aaron E Miller, Karthinathan Thangavelu, Myriam Benamor, Philippe Truffinet, Paul W O'Connor
Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse rate and disability worsening across patient subgroups defined according to prior disease-modifying therapy exposure. This analysis provides further supportive evidence for a consistent effect of teriflunomide across a broad range of patients with relapsing MS, including patients who have used and discontinued other disease-modifying therapies...
March 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28303762/tlr9-based-immunotherapy-for-the-treatment-of-allergic-diseases
#17
Shokrollah Farrokhi, Narjes Abbasirad, Ali Movahed, Hossein Ali Khazaei, Masoud Pishjoo, Nima Rezaei
Toll-like receptors (TLRs), a family of pattern recognition receptors expressed on many cell types of innate immunity, recognize the pathogen-associated molecular patterns of microbes. The hygiene hypothesis suggests that a reduced microbial exposure in early childhood increases the susceptibility to allergic diseases due to deviation in development of the immune system. TLRs are key roles in the right and healthy direction of adaptive immunity with the induction of T-helper 2 toward Th1 immune responses and regulatory T cells...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28303731/the-value-of-microparticles-in-detecting-acute-rejection-episodes-after-liver-transplantation
#18
Mehmet Haluk Morgul, Katrin Splith, Christoph Leonhardt, Nathanael Raschzok, Anja Reutzel-Selke, Rosa Bianca Schmuck, Andreas Andreou, Georgi Atanasov, Christian Benzing, Felix Krenzien, Hans-Michael Hau, Philipp Felgendreff, Sergej Klunk, Johann Pratschke, Igor Maximillian Sauer, Moritz Schmelzle
CONTEXT: Non-invasive markers for diagnosis of acute rejection (AR) following liver transplantation have not been developed, yet. OBJECTIVE: We analysed the correlation of plasma microparticle levels (MP) with AR. MATERIALS AND METHODS: MP (CD4, CD8, CD25, CD31, MHC) of 11 AR patients and 11 controls were analysed within the first week after transplantation. RESULTS: CD4, CD8 and CD31 positive MP were higher in the AR, whereas overall MP count, CD25 and MHCI positive MP proportions did not differ between both groups...
March 17, 2017: Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
https://www.readbyqxmd.com/read/28303530/a-randomized-open-label-multicenter-phase-ii-study-evaluating-the-efficacy-and-safety-of-bth1677-1-3-1-6-beta-glucan-imprime-pgg-in-combination-with-cetuximab-and-chemotherapy-in-patients-with-advanced-non-small-cell-lung-cancer
#19
M Thomas, P Sadjadian, J Kollmeier, J Lowe, P Mattson, J R Trout, M Gargano, M L Patchen, R Walsh, M Beliveau, J F Marier, N Bose, K Gorden, F Schneller
Introduction BTH1677, a 1,3-1,6 beta-glucan immunomodulator, stimulates a coordinated anti-cancer immune response in combination with anti-tumor antibody therapies. This phase II study explored the efficacy, pharmacokinetics (PK), and safety of BTH1677 combined with cetuximab/carboplatin/paclitaxel in untreated stage IIIB/IV non-small cell lung cancer (NSCLC) patients. Methods Patients were randomized 2:1 to the BTH1677 arm (N=60; BTH1677, 4 mg/kg, weekly; cetuximab, initial dose 400 mg/m(2) and subsequent doses 250 mg/m(2), weekly; carboplatin, 6 mg/mL/min AUC (area-under-the-curve) by Calvert formula, once each 3-week cycle [Q3W]); and paclitaxel, 200 mg/m(2), Q3W) or Control arm (N=30; cetuximab/carboplatin/paclitaxel as above)...
March 16, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28303134/bronchial-epithelial-cells-from-asthmatic-patients-display-less-functional-hla-g-isoform-expression
#20
Federico Carlini, Christophe Picard, Céline Garulli, David Piquemal, Pierre Roubertoux, Jacques Chiaroni, Pascal Chanez, Delphine Gras, Julie Di Cristofaro
Not all asthmatic patients adequately respond to current available treatments, such as inhaled corticosteroids or omalizumab(®). New treatments will aim to target the bronchial epithelium-immune response interaction using different pathways. HLA-G is involved in immunomodulation and may promote epithelial cell differentiation and proliferation. HLA-G protein has several isoforms generated by alternative splicing that might have differential functionalities. HLA-G protein expression and genetic polymorphisms have been reported to be associated with asthma...
2017: Frontiers in Immunology
keyword
keyword
17123
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"